Efficacy and Safety of Total Glucosides of Paeony Combined With NB-UVB on Treating Vitiligo

xjpfW

Status: Completed

Conditions: Vitiligo

Treatments: Device: Narrow band-ultraviolet b（NB-UVB）; Drug: Total Glucosides of Paeony(TGP) analogue; Drug: Total Glucosides of Paeony(TGP)

Study type: Interventional

Funder types: Other

Identifiers

NCT03608917

XijingH-PF-20180116

Details and patient eligibility

About

1. Total Glucosides of Paeony(TGP) As a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）. Paeoniflorin accounted for more than 90% of the TGP, is the main active ingredient of white peony root.By pharmacological and clinical studies of TGP, it have found that the mechanism of TGP is unique and mainly acts on the upstream of the immune response - inhibiting the presentation of antigens. It is different from immunosuppressive agents on T, B lymphocytes, or hormones and other drugs acting on the whole process.
2. Vitiligo Vitiligo is a pigment deprived skin disease caused by the destruction of melanocytes, the global incidence of about 1%. The pathogenesis is not yet clear, the current study shows that oxidative stress and autoimmunity is an important part of its occurrence and development.
3. The basic and clinical research of TGP used in vitiligo The ratio of cluster of differentiation 4+ / cluster designation 8+ T cell vs. cluster of differentiation 4+ chronotropic dose 25+ in the peripheral blood of patients with vitiligo could be significantly increase, after patients treatment by TGP combined with tacrolimus. Thereby enhancing the patient's maintenance of immune self-stability and Immune tolerance ability, promoting the healing of skin lesions. It showed significant effect in stable vitiligo,when patients treated by autologous epidermal grafting combined with TGP.

Enrollment: 200 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• subjects must be clinically diagnosed by the investigator to have sporadic Vitiligo in proceeding
• Vitiligo with at least 3 depigmented areas in different anatomy areas including：1%~50% of the total body surface area (BSA) in （face /trunk/limbs）,the minimum area is greater than 1 cm2 .Males or females, 18 Years to 65 Years of age at the time of signing the informed consent document.

.Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.

Exclusion criteria

• Actively spreading vitiligo,or stable vitiligo;
• Subjects with segmental, acromegaly, mucous, generalized, mixed and undetermined vitiligo.;
• Secondary vitiligo subjects with history of UV photosensitivity
• Subjects with other diseases unsuitable for ultraviolet light therapy and TGP ; .Use of vitiligo topical drugs within 2 weeks or, system treatment and phototherapy for the treatment of vitiligo within four weeks.
• History of allergy to any component of the total glucosides of paeony(TGP);
• Subjects with a history of chronic diarrhea or peptic ulcer within 1 year .Women who are pregnant or breast feeding,or preparing for pregnancy. .Subjects with serious medical diseases or history of mental system abnormal. .Use of any prior and concomitant therapy not listed above that may interfere with the objective of the study as per discretion of the investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

200 participants in 2 patient groups, including a placebo group

Treatment group

Experimental group

Description:

Drug:Total Glucosides of Paeony (TGP) 1. Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day) 2. Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally.

Treatment:

Drug: Total Glucosides of Paeony(TGP)

Device: Narrow band-ultraviolet b（NB-UVB）

Control group

Placebo Comparator group

Description:

Drug:Total Glucosides of Paeony (TGP) analogue 1. Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day) 2. Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally.

Treatment:

Drug: Total Glucosides of Paeony(TGP) analogue

Device: Narrow band-ultraviolet b（NB-UVB）